Ligand Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Ligand Pharma (LGND) Tops Q1 EPS by 40c
May 8, 2018 4:45 PM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.55, $0.40 better than the analyst estimate of $1.15. Revenue for the quarter came in at $56.2 million versus the consensus estimate of $43.02 million.
GUIDANCE:
Ligand Pharma sees FY2018 EPS of $4.85, versus the consensus of $4.67.
Ligand affirms... More
